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Because myocardial reperfusion injury may be caused by
various blood constituents, a transient period of blood-free
reperfusion was evaluated in closed chest dogs subjected to
a 90 min angioplasty balloon occlusion of the left anterior
descending coronary artery. In the treated group (n =13),
the balloon remained inflated for an additional 15 min while
the infarct vessel was perfused with an acellular oxygenated
perfluorochemical emulsion (Fluosol). The balloon was then
deflated, permitting blood reperfusion. In the control group
(n =13), the balloon was deflated after 90 min of coronary
occlusion.
One week after infarction, the area at risk was defined
in vivo by monastral blue dye staining, and the area of
myocardial necrosis was assessed using triphenyltetra-
zolium chloride staining with histologic confirmation. Ma-
jor determinants of infarct size, including rate-pressure
product, area at risk and severity of myocardial ischemia
Several major clinical trials have shown that expeditious
reperfusion of the occluded coronary artery in patients with
acute myocardial infarction results in improved recovery of
left ventricular function (1,2) and a reduced mortality rate
(3,4). However, an increasing body of experimental evi-
dence suggests that myocardial salvage is reduced by ad-
verse events occurring after reperfusion. The process
whereby necrosis of previously viable myocytes is attributed
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(assessed by the extent of ST segment elevation during
coronary occlusion), were not significantly different in the
two groups.
Treated dogs demonstrated a 47% reduction in infarct
size expressed as a percent of the area at risk compared
with control dogs (27.0 ± 4.4% versus 50.8 ± 4.4%, p <
0.01). Treated dogs also demonstrated a superior global left
ventricular ejection fraction (57.5 ± 2.5% versus 51.0 ±
2.2%, p < 0.05) and anterolateral (regional) ejection
fraction (32.6 ± 3.6% versus 19.8 ± 3.9%, p < 0.05)
compared with values in control dogs assessed by contrast
ventriculography after 1 week of reperfusion.
It is concluded that a transient period of blood-free
reperfusion with an oxygenated perfluorochemical reduces
reperfusion injury in a canine model of myocardial infarc-
tion.
(J Am Coli CardioI1990,.15:1385-93)
to reperfusion rather than to the preceding ischemic event
has been termed "reperfusion injury" (5).
Although controversy exists regarding the pathogenesis
of reperfusion injury, several recent studies (6-10) have
strongly implicated cellular elements in blood, particularly
the neutrophil. During coronary artery occlusion, neutro-
phils have been shown to gradually accumulate in the
ischemic myocardium by means of the collateral circulation
(II). With reperfusion, myocardial neutrophil accumulation
is accelerated (12). This results in tissue injury from the
release of toxic oxygen-derived free radicals and proteolytic
enzymes (13) and neutrophil plugging of the microcirculation
(14). The stimulus for this inflammatory process has not been
fully defined, but may involve neutrophil or endothelial cell
release of proinflammatory substances (superoxide anion.
leukotriene B4, platelet-activating factor) into the ischemic
microcirculation, which then amplifies neutrophil accumula-
tion.
We hypothesized that the selective perfusion of the
infarct-related artery during the initial phase of reperfusion
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with an acellular oxygen-carrying solution would permit the
resumption of aerobic metabolism while temporarily restrict-
ing the entry of potentially harmful blood constituents. In
addition, this reperfusion strategy would "wash out" proin-
flammatory substances from the ischemic microcirculation
before permitting reentry of blood elements from the native
circulation. This may reduce inflammation in the reperfused
myocardium, and thereby reduce the severity of reperfusion
injury.
The perfluorochemical emulsion Fluosol was chosen as
the acellular perfusate because it can effectively transport
oxygen to the myocardium (15,16). In addition, it has been
shown to reduce ischemia and to support contractile func-
tion during anterograde perfusion of an occluded coronary
artery in animal studies (17,18) and in patients undergoing
coronary angioplasty (19,20). Accordingly, the purpose of
this investigation was to assess whether a transient period of
blood-free reperfusion with an oxygenated perfluorochem-
ical emulsion would reduce reperfusion injury in a closed
chest canine model of myocardial infarction.
Methods
This study conformed to the guidelines specified in the
National Institutes of Health Guide for Care and Use of
Laboratory Animals and was approved by the Georgetown
University Animal Care and Use Committee.
Experimental preparation. Adult male dogs (18 to 26 kg)
(n = 59) were anesthetized with intravenous sodium thio-
pental (25 mg/kg body weight) and fentanyl citrate (10
j.Lg/kg), endotracheally intubated and ventilated (Harvard
respirator) with room air. Respiratory status was monitored
periodically with arterial blood gas determinations, and pH
was maintained at 7.4 ± 0.05. Anesthesia was maintained
throughout the study, with a constant infusion of fentanyl
citrate (10 j.Lg/kg per h); muscle relaxation was established
with pancuronium bromide (0.1 mg/kg intravenously) as
needed. A bipolar V3 chest lead (addressing the soon to be
ischemic region of the anterior wall) was attached to provide
constant electrocardiographic (ECG) and arrhythmia moni-
toring as previously described (21).
Dogs were positioned supine on the catheterization table,
and bilateral femoral cutdowns were performed. The left
femoral artery was isolated, and an 8F introducer sheath was
inserted. Under fluoroscopic guidance, a 7F micromanome-
ter-tipped pigtail catheter (SPC-474A, Millar Instruments)
was positioned in the apex of the left ventricle for continuous
monitoring of left ventricular pressure and performance of
contrast ventriculography. An 8F introducer sheath was
inserted in the right femoral artery, and an 8F hockey
stick-shaped guiding catheter (lnterventional Medical) was
used to intubate the left main coronary artery. Catheter
placement was facilitated by hand injections of small quan-
tities of iodinated contrast agent (Angiovist). Heparin (3,000
LAD Occlusion
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Figure 1. Study protocol. In the control (CONT) group (n = 13), the
angioplasty balloon was inflated in the left anterior descending
(LAD) coronary artery for 90 min, followed by balloon deflation and
unmodified blood reperfusion. The blood-free reperfusion (BFR)
group (n = 13) underwent an identical 90 min occlusion, followed by
an additional 15 min intracoronary infusion of an oxygenated
perfluorochemical emulsion (PFC) (Fluosol) during continued bal-
loon inflation. Hemodynamic measurements and contrast ventricu-
lography (DATA) were performed before occlusion, during occlu-
sion (at 60 min) and after reperfusion (at 10 min, 2 h and I week).
U) was then administered intravenously and repeated (1,000
U) during each subsequent hour until reperfusion. A 0.014
in. (0.036 cm) floppy guide wire (Advanced Cardiovascular
Systems) was advanced through the guiding catheter and
positioned in the distal portion of the left anterior descending
coronary artery. The guiding catheter was then withdrawn
slightly from the left main coronary artery (to prevent any
restriction of coronary blood flow), and baseline hemody-
namic measurements and contrast ventriculography were
performed.
A specially designed angioplasty catheter (balloon di-
mensions 3 mm width, 10 mm length; Advanced Cardiovas-
cular Systems) was then advanced through the guiding
catheter over the floppy guide wire and positioned so that the
proximal portion of the balloon was immediately distal to the
first major diagonal branch. Care was exercised to avoid
obstructing any major diagonal branches during subsequent
balloon inflation. The precise location of the angioplasty
balloon in relation to the angiographic landmarks was care-
fully noted. The angioplasty guide wire was then removed,
and the central lumen of the angioplasty catheter was flushed
with heparinized saline solution.
Study protocol (Fig. 1). Before instrumentation, the 59
dogs were randomized into one of two study groups. Be-
cause it has been previously observed (22) that perfluoro-
chemicals cause transient hypotension in 50% to 70% ofdogs
as a first dose phenomenon, animals in the treated group
were given an intravenous test dose (0.5 m\) of perfluoro-
chemical (F1uosol, Alpha Therapeutic Corporation) before
coronary instrumentation. In both groups just before balloon
inflation, lidocaine (l mg/kg) was administered intravenously
and then by a constant infusion (l mg/min) for the subse-
quent 3 h of the study. The angioplasty balloon was then
inflated to 4 atm, and complete occlusion of the left anterior
descending artery was confirmed by coronary angiography.
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In the control group, the balloon was deflated after 90 min
of coronary artery occlusion and removed, permitting un-
modified blood reperfusion. The treated group underwent an
identical period of occlusion followed by a 15 min period of
blood-free reperfusion. This was accomplished by maintain-
ing balloon inflation while perfusing the distal vessel with
oxygenated (partial pressure of oxygen [Po2] >600 mm Hg)
perfiuorochemical at 1 ml/kg per min through the central
lumen of the angioplasty catheter. This flow rate was chosen
because it approximates left anterior descending blood flow
at a heart rate of 80 to 100 beats/min (23). The perfiuoro-
chemical emulsion (previously oxygenated by gently bub-
bling 95% oxygen/5% carbon dioxide through it for 45 min)
was infused by an angiographic power injector equipped
with a 260 ml syringe (Mark IV, Medrad Corporation)
attached to the central lumen of the angioplasty catheter. At
the conclusion of the 15 min period of blood-free reperfu-
sion, the balloon was deflated and removed. Coronary artery
reperfusion was confirmed by angiography in both groups
immediately after balloon deflation.
Heart rate, left ventricular pressure and contrast ventric-
ulography were obtained at baseline before coronary occlu-
sion, at 60 min ofcoronary occlusion and after reperfusion at
10 min (when the treated group was receiving the perfluoro-
chemical infusion) and at 2 h. In addition, the ECG (V3 chest
lead) was recorded after 10 min of coronary occlusion to
assess the severity of myocardial ischemia. After 3 h of
reperfusion, all catheters were removed, the cutdowns re-
paired and the dogs allowed to recover.
One week after infarction, the dogs were reanesthetized
with intravenous sodium thiopental (25 mg/kg) and fentanyl
citrate (10 JLg/kg), intubated, ventilated and instrumented in
a manner identical to that previously described. Measure-
ments of heart rate and left ventricular pressure were then
obtained, and contrast ventriculography was performed.
To define the area at risk in vivo, the angioplasty balloon
was positioned in the left anterior descending coronary
artery at the same site as in the initial study. Lidocaine (I
mg/kg) was then administered intravenously and the balloon
inflated to 4 atm. Mter 3 to 4 min of coronary occlusion,
monastral blue dye (1 mUkg; Dupont) was infused into the
ascending aorta over 2 to 3 min, leaving the area at risk
unstained by the blue dye. The dogs were then killed with
potassium chloride (30 mEq bolus into the aortic root).
Assessment of left ventricular function. Left ventricular
function was assessed with contrast ventriculography, which
was always performed after hemodynamic measurements
were obtained. All ventriculograms were performed in a 30°
right anterior oblique projection by injecting 15 ml of iodin-
ated contrast agent at 12 ml/s with a power injector (model
2281, Cordis) and recorded on 35 mm film at 30 frames/so
Ventriculograms were analyzed by a collaborator (S.P.K. or
E.C.S.) blinded to identification of the treatment group.
End-diastolic and end-systolic images were projected on a
screen and traced. Beats following premature ventricular
contractions were excluded. Global left ventricular ejection
fraction was determined by the standard Sandler-Dodge
formula (24). Anterolateral (regional) ejection fraction was
determined by an area ejection fraction method previously
described (21). On the end-diastolic frame, a line was drawn
connecting the midpoint of the aortic valve to the apex of the
left ventricle. A perpendicular line was then drawn, bisecting
the anterior half. Anterolateral ejection fraction (EFant-lat)
was computed by the following equation:
EFant-lat (%) = (EDa - ESa)/EDa x 100,
where EDa = end-diastolic area and ESa = end-systolic
area.
Quantitation of myocardial infarct size. Immediately after
the dog was killed, the heart was removed and weighed. The
left ventricle (including the interventricular septum) was
separated from the remainder of the heart and cut into five or
six slices (1 cm thick) from apex to base, parallel to the
atrioventricular (AV) groove. The basal portion of each slice
was photographed with Ektachrome (Kodak) to define the
area at risk that was not stained by the monastral blue dye.
Each slice was then incubated in 2% triphenyltetrazolium
chloride for 10 min at 37°C to define the area of myocardial
necrosis (25). Triphenyltetrazolium chloride stains myocar-
dium containing dehydrogenase enzymes red; areas of ne-
crotic tissue depleted of these enzymes do not stain and
appear white or pale yellow. After incubation in triphenyltet-
razolium chloride, each slice was rephotographed and
weighed. The area at risk and area of necrosis were deter-
mined from tracings of enlarged projections of the photo-
graphs by a collaborator (R. V.) who did not know the
identity of the treatment groups. Computer-aided planimetry
was used to quantitate both the area at risk and the area of
necrosis, which were corrected for the weight of each slice.
These values were then summated for the entire left ventri-
cle. Area of necrosis was expressed as a percent of the area
at risk and of the left ventricle. Heart slices were then fixed
by immersion in 10% phosphate-buffered formalin.
Because the accuracy of the triphenyltetrazolium chlo-
ride method to determine myocardial infarct size has been
questioned by some investigators (26,27), histologic tech-
niques were also used to assess infarct size in seven ran-
domly selected dogs from each group. Mter ~3 days of
fixation, heart slices were dehydrated and embedded in
paraffin. Microscopic sections (7 JLm thick) from each slice
were stained with hematoxylin-eosin and Mallory's tri-
chrome stain, and the area of necrosis was quantitated by
using methods previously described (22).
Light microscopy. To assess the extent of infarct healing
and inflammatory infiltrate I week after infarction, semi-
quantitative analysis of infarct morphology was determined
by light microscopy on the middle two slices. Variables
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assessed included degree of infiltration with chronic inflam-
matory cells (lymphocytes) and macrophages and extent of
hemorrhagic infarction, collagen formation and fibroblast
proliferation. An average of 20 high power fields (400x) per
slide were evaluated. These variables were determined semi-
quantitatively according to the method of Romson et al. (10),
with a score of 4 representing the most dense infiltrate and 0
representing no infiltrate.
Statistical analysis. All data are presented as mean values
± SEM. Comparisons of infarct size and area at risk
between the two groups were made using Student's t test for
unpaired data. When observations were repeated over time,
a three-way analysis of variance was used to examine the
data for effects of 1) treatment (control versus blood-free
reperfusion), 2) dog to dog variability within treatment
groups, and 3) time. When significant differences were
found, a multiple comparisons procedure (Tukey's test) was
used to determine at which time points the groups differed.
The correlation of extent of ST segment elevation during
coronary occlusion and infarct size (expressed as a percent
of the area at risk) was assessed by linear regression analy-
sis. Differences in the incidence of ventricular fibrillation
were assessed by Fisher's exact test. Statistical significance
was identified at p < 0.05.
To ensure that the study groups included dogs with
sufficient myocardial ischemia to produce infarction, it was
decided prospectively to exclude dogs that failed to demon-
strate >0.1 mV ST segment elevation during coronary
occlusion (recorded from a bipolar V3 chest lead addressing
the anterior wall at risk). In addition, dogs were excluded if
the area at risk was < 10% of the left ventricle. Dogs
developing ventricular fibrillation during coronary occlusion
or after reperfusion were also excluded. Defibrillation was
not attempted.
Results
Study groups: incidence of ventricular fibriUation. Of the
59 randomized dogs, 26 were included in the final analysis:
13 control dogs and 13 dogs that received transient blood-
free reperfusion with the oxygenated perfluorochemical. The
incidence of ventricular fibrillation during coronary artery
occlusion and after reperfusion is shown in Table 1. During
coronary occlusion, 13 dogs were excluded because of
ventricular fibrillation (6 control and 7 treated, p = NS). Of
the 10 dogs that were excluded because of ventricular
fibrillation during the first 3 h of reperfusion, 2 were in the
treated group and 8 were in the control group (p = 0.09),
suggesting a trend toward reduced reperfusion ventricular
fibrillation in dogs treated with transient blood-free reperfu-
sion. During the initial 15 min of reperfusion (at which time
the treated group was receiving blood-free reperfusion with
the oxygenated perfluorochemical), two control dogs but no
treated animals developed ventricular fibrillation. An addi-
Table 1. Incidence of Ventricular Fibrillation (VF) in Control and
Treated Dogs*
Occlusion Reperfusion Reperfusion
VF VF VF
Group No. (0-90 min) (0-15 min) (0-180 min)
Treated 27 7 (26%) ]t 0(0%) ]t 2 (lO%)]t
Control 32 6 (19%) 2 (8%) 8 (31%)
'During the initial 15 min of reperfusion, dogs in the group treated with
blood-free reperfusion were receiving intracoronary perfluorochemical distal
to the inflated angioplasty balloon, whereas the control group had unmodified
blood reperfusion. tThere were no significant differences between the treated
and control groups in the incidence of ventricular fibrillation.
tional six dogs (two control and four treated) were excluded
because of death between the first and second catheteriza-
tion studies. Four additional dogs (three control and one
treated) were excluded because the area at risk was <10% of
the left ventricle.
Effect on hemodynamics (Fig. 2). Baseline heart rate and
left ventricular pressure measurements in this closed chest
preparation were comparable to those observed in studies
using conscious dogs (23). Hemodynamic variables (heart
rate and left ventricular systolic and diastolic pressure) and
rate-pressure product (an index of myocardial oxygen de-
mand) were similar for both groups throughout the course of
the experiment.
Effect on the ST segment and hematologic variables. The
severity of ischemia, as measured by the extent of ST
segment elevation after 10 min of coronary occlusion, was
similar in the treated and control groups (0.59 ± 0.07 versus
0.57 ± 0.09 mV, P = NS). Baseline hematologic evaluation
was similar in the two groups for hematocrit (39 ± 2% versus
41 ± 2%; p = NS), white blood count (11.9 ± 1.1 versus 11.6
± 1.2 . 103/ ILl, P = NS) and percent neutrophil count (63 ±
2% versus 63 ± 4%, P = NS).
Effect on regional and global left ventricular function (Fig.
3). At baseline, the treated and control dogs had similar
values for anterolateral (regional) left ventricular ejection
fraction (41.5 ± 3.1% versus 43.5 ± 2.3%, p = NS) and
global ejection fraction (59.3 ± 2.5% versus 61.7 ± 1.9%,
P = NS). After 60 min of coronary artery occlusion, both
groups demonstrated dyskinesia in the anterolateral region
and a similar degree of impairment of global left ventricular
function. During the initial 10 min of reperfusion (when the
treated dogs were receiving blood-free reperfusion) and at 2
h after reperfusion, regional and global contractile function
were comparably depressed in both groups. After 1week of
reperfusion, the treated dogs demonstrated better regional
(32.6 ± 3.6% versus 19.8 ± 3.9%, p < 0.05) and global (57.5
± 2.5% versus 51.0 ± 2.2%, p < 0.05) left ventricular
function than did the control dogs.
Effect on myocardial infarct size (Fig. 4). Despite a com-
parable area at risk in the treated and control groups (22.5 ±
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1.7% versus 20.7 ± 1.9%, respectively, p = NS), the dogs
that received transient blood-free reperfusion with oxygen-
ated perfluorochemical demonstrated a 47% reduction in
infarct size (determined by triphenyltetrazolium chloride
Figure 2. Hemodynamic effects of blood-free reperfusion (BFR)
versus control. No statistically significant differences were observed
between groups. Base = baseline; HR = heart rate; LVEDP = left
ventricular end-diastolic pressure; LVPSP = left ventricular peak
systolic pressure; aee = coronary occlusion (60 min); RPP =
rate-pressure product.
Figure 3. Effect of blood-free reperfusion (BFR) on left ventricular
function (as measured by ejection fraction) in the anterolateral
region (top) and globally (bottom). e = control; other abbreviations
as in Figure 2.
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staining) expressed as a percent of the area at risk (27.0 ±
4.4% versus 50.8 ± 4.4%, p < 0.01). In addition, the treated
dogs had a significant reduction in infarct size expressed as
a percent of the total left ventricle (6.3 ± 1.4% versus 10.9 ±
1.7%, p < 0.05).
Histologically determined infarct size (from seven ran-
Figure 4. Effect of blood-free reperfusion (BFR) on myocardial
infarct size determined by triphenyltetrazolium chloride staining.
AN = area of necrosis; AR = area at risk; LV = left ventricle.
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differences were observed in collagen deposition or fibro-
blast or macrophage infiltration. Neutrophils were absent in
the treated group and rarely seen in the control group,
indicating appropriate healing for the age of the infarct in all
animals.
Discussion
This study demonstrates that reperfusion injury can be
reduced by modifying the initial 15 min of reperfusion by
perfusing the infarct-related artery with an oxygenated acel-
lular perfluorochemical emulsion during simultaneous re-
striction of anterograde blood flow. This is supported by a
finding that dogs treated with the blood-free reperfusion
strategy had a marked reduction in myocardial infarct size,
superior left ventricular function and a trend toward a
reduced incidence of reperfusion ventricular fibrillation com-
pared with dogs that did not receive such treatment. The
observed benefits of blood-free reperfusion cannot be ex-
plained by intergroup differences in major predictors of
myocardial infarct size, such as severity of ischemia, ana-
tomic area at risk or myocardial oxygen demand.
Potential benefits of delaying entry of blood constituents
during early reperfusion. Of the several potentially harmful
blood components, neutrophils are probably the most impor-
tant (6-10), based on their ability to injure viable myocytes
by releasing toxic free radicals and proteolytic enzymes (13)
or by obstructing microcirculatory flow (14). Platelets also
accumulate within the reperfused myocardium (28,29) and
may contribute to altered microcirculatory flow by means of
formation of microthrombi or release of potent vasoconstric-
tors (30). In addition, platelet-derived mediators may aug-
ment neutrophil infiltration into the reperfused myocardium
(31,32). Noncellular blood components such as free fatty
acids (33,34) and catecholamines (35,36) may also be harm-
ful.
Although blood constituents may injure the newly reper-
fused myocardium, their entry was only temporarily delayed
in the present investigation. However, during this interval of
restricted blood entry, the infarct-related artery was simul-
taneously perfused with an oxygenated perfluorochemical
emulsion having a lower viscosity than that of blood (20).
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Figure 5. Relation between ST segment elevation and myocardial
infarct size. Regression lines have been drawn for both groups. The
control group demonstrates a significant correlation between these
variables (r = 0.84, p < 0.001), whereas the treated group shows no
significant correlation (r = 0.17, p = NS). Abbreviations as in Figure
4.
ST SEGMENT ELEVATION (mV)
domly selected dogs in each group) yielded results closely
comparable to those obtained with triphenyltetrazolium
chloride. Treated dogs demonstrated a substantially smaller
infarct size expressed as a percent of the area at risk than
that of control dogs (25.2 ± 6.0% versus 53.0 ± 7.1%,
respectively, p < 0.02) and a smaller infarct size expressed
as a percent of the left ventricle (5.6 ± 1.6% versus 10.8 ±
1.7%, respectively, p < 0.05).
Relation of infarct size to severity of ischemia (Fig. 5). For
the control group, there was a highly significant correlation
between extent of ST segment elevation after 10 min of
coronary occlusion and ultimate infarct size expressed as a
percent of area at risk (p < 0.001, r = 0.84). In contrast, the
treated group demonstrated no significant correlation be-
tween these variables (p = NS, r = 0.17).
Light microscopy (Table 2). Infarct healing in the two
groups was incomplete at 1week. In the dogs that underwent
blood-free reperfusion, the infarct was predominantly suben-
docardial and patchy, whereas the control dogs had a larger,
more confluent infarct. In addition, the infarction in the
treated group tended to be associated with a lower incidence
of hemorrhage (p = 0.08) and fewer chronic inflammatory
cells (p = 0.06) than in the control group. No significant
Table 2. Semiquantitative Analysis by Light Microscopy
Chronic
Hemorrhagic Inflammatory
Group No. Infarction Macrophages Cells Fibroblasts Collagen
Treated 7 0.9 ± 0.4 J* 1.3 ± 0.2 J* 0.1 ± 0.1 J* 1.7 ± OJ J* 1.3 ± 0.2 J*
Control 7 2.0 ± 0.5 1.I ± 0.1 0.6 ± 0.2 2J ± 0.3 1.8 ± 0.2
Data expressed as mean values ± SEM. Specimens were graded on a scale of 0 to 4. A score of 0 represented no infiltrate and 4 represented an extensive
infiltrate. *There were no significant differences between the treated and control groups in any variable.
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The resulting washout of the ischemic microcirculation may
be beneficial by facilitating the removal of neutrophils (11)
and platelet aggregates (28,37) that accumulate within the
ischemic microcirculation during coronary occlusion. This
effect could improve microcirculatory flow after blood reper-
fusion by diminishing the no reflow phenomenon (38,39). In
addition, clearing of free radicals (13,40) from the microcir-
culation may further reduce tissue injury.
Washout of proinflammatory mediators such as superox-
ide anion (13), platelet-activating factor (31,41,42), leukotri-
ene B4 (43) and complement components (44,45) may also be
beneficial. With the onset of blood reperfusion, these medi-
ators attract and activate neutrophils entering the reperfused
myocardium (12), thereby amplifying the inflammatory pro-
cess. By clearing proinflammatory mediators from the mi-
crocirculation before blood elements are permitted access to
the regional circulation, the inflammatory process and sub-
sequent tissue injury may be diminished.
Blood-free reperfusion with an oxygenated perfluoro-
chemical emulsion may also facilitate the removal of meta-
bolic by-products while delivering oxygen to the myocar-
dium. This may permit the resumption of aerobic
metabolism (15,16) and the initiation of cellular repair,
perhaps rendering the myocardium less susceptible to injury
by blood components and free radicals.
Benefits attributable to the perfluorochemical emulsion.
Another possible explanation for the benefits observed may
be directly attributable to the perfluorochemical emulsion.
Previous studies (46,47) have shown that perfluorochemicals
reduce infarct size in dogs with prolonged coronary occlu-
sion without reperfusion. In more recent studies, Forman et
al. (22,48) infused the oxygenated perfluorochemical emul-
sion Fluosol into the nonoccluded left main coronary artery
during the initial 15 min of reperfusion after a 90 min
coronary occlusion and demonstrated a significant reduction
in infarct size and improved left ventricular function. The
benefits observed were comparable to those observed in our
study despite the absence of simultaneous balloon occlusion
during Fluosol infusion. These results suggest that perfluo-
rochemicals may diminish reperfusion injury independent of
the mode of intracoronary administration.
There are several mechanisms by which perfiuorochemi-
cals may reduce reperfusion injury. One important mecha-
nism may be perfluorochemical-induced neutrophil dysfunc-
tion. Previous in vitro experiments (49,50) have shown that
perfluorochemicals inhibit several important neutrophil
functions, including chemotaxis, phagocytosis and adher-
ence. In a dog model of coronary occlusion and reperfusion,
Bajaj et al. (51) demonstrated that infusion of Fluosol (25
mVkg intravenously) before reperfusion inhibited neutrophil
function in vivo, reduced infarct size and improved contrac-
tile function.
The small size of the perfluorochemical particles (about
1/9000 the volume of a red blood cell) may also be beneficial.
These oxygen-carrying particles may be superior to red
blood cells in gaining entry into myocardial regions where
blood flow is impaired by cellular aggregates or endothelial
swelling (15).
Possible limitations of methods used. The severity of
myocardial ischemia produced by coronary occlusion varies
considerably from dog to dog, primarily because of differ-
ences in collateral flow (26). To control for this major
determinant of myocardial infarct size, investigators (26,52)
have emphasized the importance of measuring collateral
blood flow with microspheres in canine models of myocar-
dial ischemia. Another method to assess the severity of
myocardial ischemia produced by coronary occlusion is
measurement of the extent of ST elevation (6). Prior studies
(53,54) have demonstrated a significant correlation between
this technique and microsphere-determined collateral blood
flow. To further enhance the sensitivity of this method, we
measured the extent of ST segment elevation from a bipolar
V3 chest lead addressing the area at risk (21,55). The
demonstration in control animals of a highly significant
correlation between the extent of ST elevation and myocar-
dial infarct size (as a percent of the area at risk) suggests that
this variable is a sensitive measure of the severity of myo-
cardial ischemia and is, therefore, an important determinant
of myocardial infarct size.
Although we postulated that blood-free reperfusion
would reduce the acute inflammatory response after reper-
fusion, our study design precluded histologic evaluation of
this possibility. After 1 week of reperfusion, the acute
inflammatory response had resolved and only rare neutro-
phils were seen. Histologic evaluation of the acute inflam-
matory response would have necessitated terminating reper-
fusion after 24 h; however, this would have severely
compromised our assessment of left ventricular function
because of the presence of a large amount of stunned
myocardium (56). One week of reperfusion was chosen to
better assess ultimate regional and global left ventricular
function by permitting more complete recovery of stunned
myocardium.
Clinical implications. These results may have clinical
application in the management of patients undergoing coro-
nary angioplasty during the early phase of myocardial infarc-
tion. Although intravenous thrombolytic therapy is recom-
mended for the majority of patients with acute myocardial
infarction (2-4), coronary angioplasty may be indicated in
patients who fail to exhibit reperfusion and in patients in
whom thrombolytic therapy is contraindicated (57). For
these patients, the presence of an angioplasty catheter within
the infarct-related coronary artery provides an opportunity
to locally infuse agents that reduce reperfusion injury. Our
results suggest that a transient period of blood-free reperfu-
sion with the oxygenated perfluorochemical emulsion Fluo-
sol may be clinically beneficial in patients with acute infarc-
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tion by improving left ventricular function and reducing
myocardial infarct size without delaying infarct healing.
We gratefully acknowledge Virginia Lewis for her help in the preparation of
the manuscript.
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